Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12568580 | 0.88 | RECQL (0.33) | RECQL | |
| SCHEMBL43231 | 0.84 | HPGD (0.36) | — | |
| SCHEMBL28333093 | 0.83 | TERT (0.34) | RECQL | |
| SCHEMBL8735537 | 0.81 | HPGD (0.37) | — | |
| SCHEMBL4204236 | 0.81 | PSMB8 (0.32) | — | |
| SCHEMBL27324540 | 0.81 | MGLL (0.30) | — | |
| SCHEMBL9315493 | 0.81 | — | — | |
| SCHEMBL12386541 | 0.81 | HPGD (0.36) | RECQL | |
| SCHEMBL22005285 | 0.81 | GAA (0.33) | RECQL | |
| SCHEMBL22005196 | 0.81 | RECQL (0.33) | RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10351830-B2 | Conjugates for assays for oxycodone and oxymorphone | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-10351830-B2 | Conjugates for assays for oxycodone and oxymorphone | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2019-07-16 | — | — | US | disclosed |
| US-20170362579-A1 | CONJUGATES FOR ASSAYS FOR OXYCODONE AND OXYMORPHONE | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-12-21 | — | — | US | disclosed |
| US-20170362579-A1 | CONJUGATES FOR ASSAYS FOR OXYCODONE AND OXYMORPHONE | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2017-12-21 | — | — | US | disclosed |
| EP-3234604-A2 | CONJUGATES FOR ASSAYS FOR OXYCODONE AND OXYMORPHONE | Siemens Healthcare Diagnostics Inc. (US) | 2017-10-25 | — | — | EP | disclosed |
| WO-2016100113-A2 | CONJUGATES FOR ASSAYS FOR OXYCODONE AND OXYMORPHONE | SIEMENS HEALTHCARE DIAGNOSTICS INC. (US) | 2016-06-23 | — | — | WO | disclosed |
| US-9096653-B2 | Multicomponent vaccine for malaria providing long-lasting immune responses against plasmodia | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2015-08-04 | — | — | US | disclosed |
| US-20150050314-A1 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICE (US) | 2015-02-19 | — | — | US | disclosed |
| US-8900599-B2 | Conjugates of Plasmodium falciparum surface proteins as malaria vaccines | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2014-12-02 | — | — | US | disclosed |
| US-20130216570-A1 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA | The United States of America, as represented by he Secretary, Department of Health and Human | 2013-08-22 | — | — | US | disclosed |
| US-20070218506-A1 | Immunoassays for Buprenorphine and Norbuprenorphine | DADE BEHRING INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-20070218506-A1 | Immunoassays for Buprenorphine and Norbuprenorphine | DADE BEHRING INC. (US) | 2007-09-20 | — | — | US | disclosed |
| US-7220842-B2 | Immunoassays for buprenorphine and norbuprenorphine | DADE BEHRING INC. (US) | 2007-05-22 | — | — | US | disclosed |
| EP-1756570-A2 | IMMUNOASSAYS FOR BUPRENORPHINE AND NORBUPRENORPHINE | DADE BEHRING INC. (US) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005103697-A2 | IMMUNOASSAYS FOR BUPRENORPHINE AND NORBUPRENORPHINE | DADE BEHRING INC. (US) | 2005-11-03 | — | — | WO | disclosed |
| US-20050221405-A1 | Immunoassays for buprenorphine and norbuprenorphine | SIEMENS HEALTHCARE DIAGNOSTICS INC. | 2005-10-06 | — | — | US | disclosed |
| EP-0144154-B1 | PROTEIN CONJUGATES OF PENICILLOIC ACID, THEIR PREPARATION AND USE | SYNTEX (U.S.A.) INC. (US) | 1989-07-12 | — | — | EP | disclosed |
| US-4816391-A | LABELS, ANTIBIOTICS, POLYAMINES | SYNTEX (U.S.A.) INC. (US) | 1989-03-28 | — | — | US | disclosed |
| US-4596768-A | Combining assay sample, enzyme-penicilloic acid conjugate and support containing antibodies, separating support, determining enzyme activity to indicate presence of penicilloic acid | SYNTEX (U.S.A.) INC. (US) | 1986-06-24 | — | — | US | disclosed |
| EP-0144154-A1 | Protein conjugates of penicilloic acid, their preparation and use | SYNTEX (U.S.A.) INC. (US) | 1985-06-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150050314-A1 | CONJUGATES OF PLASMODIUM FALCIPARUM SURFACE PROTEINS AS MALARIA VACCINES | CD4, RPS25, OSBP2 | RECQL 3665/4885 |
| US-20130216570-A1 | MULTICOMPONENT VACCINE FOR MALARIA PROVIDING LONG-LASTING IMMUNE RESPONSES AGAINST PLASMODIA | CD47, NASP, CD69 | RECQL 822/4885 |
| US-20170362579-A1 | CONJUGATES FOR ASSAYS FOR OXYCODONE AND OXYMORPHONE | OPRK1, OPRM1, OPRL1 | RECQL 1555/4885 |
| US-20070218506-A1 | Immunoassays for Buprenorphine and Norbuprenorphine | HLA-B, HLA-C, SHBG | RECQL 3457/4885 |
| US-10351830-B2 | Conjugates for assays for oxycodone and oxymorphone | OPRK1, OPRM1, OPRL1 | RECQL 1555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.